Bayesian Capital Management’s Medpace MEDP Stock Holding History

Bayesian Capital Management’s Portfolio MEDP Stock Details MEDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,841	Closed	-$2.4M	–	980
2023 Q4	$2.4M	Buy	+7,841	New	+$2.12M	0.26%	108
2023 Q3	–	Sell	-9,026	Closed	-$2.17M	–	865
2023 Q2	$2.17M	Buy	+9,026	New	+$1.87M	0.23%	112
2023 Q1	–	Sell	-4,520	Closed	-$960K	–	974
2022 Q4	$960K	Buy	4,520 +2,700	+148%	+$539K	0.14%	189
2022 Q3	$286K	Sell	1,820 -3,500	-66%	-$559K	0.06%	428
2022 Q2	$796K	Buy	+5,320	New	+$770K	0.15%	206
2020 Q2	–	Sell	-7,458	Closed	-$547K	–	671
2020 Q1	$547K	Buy	7,458 +3,200	+75%	+$278K	0.12%	267
2019 Q4	$358K	Sell	4,258 -5,400	-56%	-$418K	0.06%	383
2019 Q3	$812K	Buy	+9,658	New	+$730K	0.15%	187
2019 Q1	–	Sell	-20,258	Closed	-$1.07M	–	681
2018 Q4	$1.07M	Sell	20,258 -16,800	-45%	-$922K	0.22%	142
2018 Q3	$2.22M	Buy	+37,058	New	+$2.03M	0.36%	65

Other funds holding MEDP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Bayesian Capital Management's MEDP Position: Q1 2024 in Review

Bayesian Capital Management sold out of Medpace (MEDP) in Q1 2024, closing a stake of 7,841 shares — an estimated $2.4M sold.

Bayesian Capital Management first reported a position in MEDP in Q3 2018 and held it in 10 quarters. The position peaked at $2.4M in Q4 2023. 597 funds tracked by Wall St. Rank hold MEDP as of Q1 2024.

Bayesian Capital Management reported no remaining Medpace position as of Q1 2024 after selling out during the quarter.
Bayesian Capital Management sold 7,841 Medpace shares in Q1 2024, an estimated $2.4M.
Bayesian Capital Management first reported a position in Medpace in Q3 2018 and held it in 10 quarters.
Bayesian Capital Management's Medpace position peaked at $2.4M in Q4 2023.
597 funds tracked by Wall St. Rank held Medpace as of Q1 2024.

Based on Bayesian Capital Management's 13F filing for Q1 2024, filed 15 May 2024.